XOMA Corporation (NasdaqGM:XOMA) acquired Rights to Ebopiprant from ObsEva SA (NasdaqGS:OBSV) for $113 million on November 22, 2022. The sale proceeds are expected to enable ObsEva to resolve its current over-indebtedness position and to withdraw its pending Swiss moratorium proceedings. The proceeds are also expected to position ObsEva to satisfy Nasdaq stockholders equity requirement for continued public listing. XOMA will now be entitled to receive up to $475 million in development, regulatory, and sales-based milestone payments under the ObsEva license agreement. Torreya acted as the exclusive financial advisor to ObsEva SA.

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of Rights to Ebopiprant from ObsEva SA (NasdaqGS:OBSV) on November 22, 2022.